Skip to content
Original Research
J Clin Psychiatry
May 2026
Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial
Full Article
Read the complete peer-reviewed article in J Clin Psychiatry.
Article Summary
Adults with ADHD commonly present with depression and anxiety symptoms, yet these patients are routinely excluded from ADHD trials, leaving clinicians to treat a high-burden population with limited evidence. This study addresses whether viloxazine ER can improve ADHD symptoms in adults who also have prominent mood and/or anxiety symptoms while being used alone or alongside other psychiatric medications.
FAQ
Did viloxazine ER improve ADHD symptoms in adults who also had depression or anxiety symptoms?
10 questions
Key Takeaways
In this symptomatic comorbid population, ADHD improvement was substantial by week 14/EOS, with mean (SD) AISRS and ASRSv1.1-SC total score changes of −17.3 (11.34) and −28.4 (14.89), and 71.8% and 45.6% of participants achieved ≥30% and ≥50% AISRS reduction, respectively.
6 takeaways
Clinical Guide
How should clinicians monitor safety after starting viloxazine ER in adults with ADHD and comorbid depression and/or anxiety symptoms?
7 steps
Clinical Guide
How should clinicians initiate viloxazine ER in adults with ADHD who also have prominent depression and/or anxiety symptoms?
6 steps